Press Releases
May 12, 2022
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 10, 2022
Wave Life Sciences to Present at Upcoming Investor Conferences
May 05, 2022
Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022
Apr 25, 2022
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD
Apr 19, 2022
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Apr 04, 2022
Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004
Mar 21, 2022
Wave Life Sciences to Present at Stifel 2022 CNS Days
Mar 15, 2022
Wave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scientific and Industry Meetings
Mar 07, 2022
Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme
Mar 03, 2022
Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update